At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NUVB Nuvation Bio, Inc.
Pre-Mkt 03-31 04:14:23 EDT
4.05
-0.20
-4.71%
High4.32Low4.05Vol3.55M
Open4.25D1 Closing4.25Amplitude6.35%
Mkt Cap1.41BTradable Cap935.74MTotal Shares347.60M
T/O14.69MT/O Rate1.53%Tradable Shares231.05M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Nuvation Bio (NUVB) Receives a Buy from Wedbush
TIPRANKS  ·  03-27
Nuvation Bio (NUVB) Receives a Buy from Wedbush
Nuvation Bio Price Target Maintained With a $11.00/Share by Wedbush
Dow Jones  ·  03-27
Nuvation Bio Price Target Maintained With a $11.00/Share by Wedbush
March 2026's Promising Penny Stocks To Watch
Simply Wall St.  ·  03-27
March 2026's Promising Penny Stocks To Watch
Nuvation Bio and Eisai’s MAA for taletrectinib in NSLC accepted in Europe
TIPRANKS  ·  03-27
Nuvation Bio and Eisai’s MAA for taletrectinib in NSLC accepted in Europe
Nuvation Bio shares rise; EMA validates taletrectinib MAA for advanced ROS1+ NSCLC in Europe
Reuters  ·  03-27
Nuvation Bio shares rise; EMA validates taletrectinib MAA for advanced ROS1+ NSCLC in Europe
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced Ros1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
THOMSON REUTERS  ·  03-27
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced Ros1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Swings?
Simply Wall St.  ·  03-20
Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Swings?
Nuvation Bio to present updated IBTROZI trial data at AACR Annual Meeting 2026
Reuters  ·  03-18
Nuvation Bio to present updated IBTROZI trial data at AACR Annual Meeting 2026
Nuvation Bio to present TRUST-I and TRUST-II taletrectinib data showing 50-month median response duration in TKI-naïve ROS1+ NSCLC
Reuters  ·  03-18
Nuvation Bio to present TRUST-I and TRUST-II taletrectinib data showing 50-month median response duration in TKI-naïve ROS1+ NSCLC
A Look At Nuvation Bio (NUVB) Valuation After Its 2025 Results Show Revenue Growth And A Narrowed Net Loss
Simply Wall St.  ·  03-11
A Look At Nuvation Bio (NUVB) Valuation After Its 2025 Results Show Revenue Growth And A Narrowed Net Loss
Nuvation Bio falls -25.3%
TIPRANKS  ·  03-04
Nuvation Bio falls -25.3%
Nuvation Bio’s Taletrectinib Outlook Clouded by Commercialization and Partner Execution Risks
TIPRANKS  ·  03-04
Nuvation Bio’s Taletrectinib Outlook Clouded by Commercialization and Partner Execution Risks
Stock Track | Nuvation Bio Soars 5.50% in Post-Market on Positive Analyst Ratings and Maintained Buy Recommendations
Stock Track  ·  03-04
Stock Track | Nuvation Bio Soars 5.50% in Post-Market on Positive Analyst Ratings and Maintained Buy Recommendations
Nuvation Bio Is Maintained at Neutral by UBS
Dow Jones  ·  03-04
Nuvation Bio Is Maintained at Neutral by UBS
Nuvation Bio Plunges on Higher Discontinuations in Ibtrozi Launch
Dow Jones  ·  03-04
Nuvation Bio Plunges on Higher Discontinuations in Ibtrozi Launch
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Nuvation Bio (NUVB)
TIPRANKS  ·  03-04
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Nuvation Bio (NUVB)
Nuvation Bio falls -26.1%
TIPRANKS  ·  03-03
Nuvation Bio falls -26.1%
Stock Track | Nuvation Bio Plummets 25.26% Intraday on Earnings Miss and Analyst Downgrade
Stock Track  ·  03-03
Stock Track | Nuvation Bio Plummets 25.26% Intraday on Earnings Miss and Analyst Downgrade
RBC Raises Price Target on Nuvation Bio to $13 From $12, Keeps Outperform, Speculative Risk
MT Newswires Live  ·  03-03
RBC Raises Price Target on Nuvation Bio to $13 From $12, Keeps Outperform, Speculative Risk
Truist Financial Keeps Their Buy Rating on Nuvation Bio (NUVB)
TIPRANKS  ·  03-03
Truist Financial Keeps Their Buy Rating on Nuvation Bio (NUVB)

Introduction

Company Name.
Nuvation Bio, Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung , M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco .
Issue price:
--